Fidelity Investments’s Acorda Therapeutics ACOR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-9
Closed -$114 5753
2024
Q1
$114 Buy
+9
New +$131 ﹤0.01% 4964
2023
Q3
Sell
-1
Closed -$13 5663
2023
Q2
$13 Buy
+1
New +$12 ﹤0.01% 5250
2020
Q3
Sell
-5,264
Closed -$464K 4105
2020
Q2
$464K Sell
5,264
-37,999
-88% -$4.02M ﹤0.01% 2522
2020
Q1
$4.84M Sell
43,263
-9,863
-19% -$1.94M ﹤0.01% 1948
2019
Q4
$13M Sell
53,126
-6,277
-11% -$1.58M ﹤0.01% 1751
2019
Q3
$20.5M Buy
59,403
+135
+0.2% +$73.4K ﹤0.01% 1561
2019
Q2
$54.6M Buy
59,268
+583
+1% +$716K 0.01% 1176
2019
Q1
$93.6M Buy
58,685
+444
+0.8% +$800K 0.01% 939
2018
Q4
$109M Buy
58,241
+643
+1% +$1.4M 0.01% 812
2018
Q3
$136M Buy
57,598
+6,035
+12% +$18.7M 0.02% 814
2018
Q2
$178M Buy
51,563
+141
+0.3% +$432K 0.02% 713
2018
Q1
$146M Buy
51,422
+2,795
+6% +$8.37M 0.02% 820
2017
Q4
$125M Sell
48,627
-9,686
-17% -$27.5M 0.01% 893
2017
Q3
$165M Sell
58,313
-11
-0% -$29K 0.02% 758
2017
Q2
$138M Buy
58,324
+2,907
+5% +$5.76M 0.02% 825
2017
Q1
$140M Sell
55,417
-2,225
-4% -$6.4M 0.02% 851
2016
Q4
$130M Sell
57,642
-33
-0.1% -$78.5K 0.02% 856
2016
Q3
$145M Buy
57,675
+192
+0.3% +$573K 0.02% 815
2016
Q2
$176M Buy
57,483
+7,215
+14% +$23.5M 0.02% 720
2016
Q1
$160M Sell
50,268
-3,676
-7% -$15.3M 0.02% 760
2015
Q4
$277M Buy
53,944
+386
+0.7% +$1.69M 0.04% 518
2015
Q3
$170M Buy
53,558
+69
+0.1% +$268K 0.02% 710
2015
Q2
$214M Buy
53,489
+270
+0.5% +$1.04M 0.03% 662
2015
Q1
$213M Buy
53,219
+1,916
+4% +$8.78M 0.03% 665
2014
Q4
$252M Buy
51,303
+607
+1% +$2.6M 0.03% 578
2014
Q3
$206M Buy
50,696
+11,244
+29% +$42.2M 0.03% 650
2014
Q2
$160M Buy
39,452
+3,766
+11% +$15.4M 0.02% 765
2014
Q1
$162M Buy
35,686
+5,499
+18% +$22.2M 0.02% 735
2013
Q4
$106M Sell
30,187
-16,943
-36% -$66.1M 0.01% 950
2013
Q3
$194M Sell
47,130
-2,748
-6% -$11.8M 0.03% 629
2013
Q2
$197M Buy
+49,878
New +$205M 0.03% 591

Other funds holding ACOR

Fidelity Investments's ACOR Position: Q2 2024 in Review

Fidelity Investments sold out of Acorda Therapeutics (ACOR) in Q2 2024, closing a stake of 9 shares — an estimated $114 sold.

Fidelity Investments first reported a position in ACOR in Q2 2013 and held it in 31 quarters. The position peaked at $277M in Q4 2015. 2 funds tracked by Wall St. Rank hold ACOR as of Q2 2024.

  • Fidelity Investments reported no remaining Acorda Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Fidelity Investments sold 9 Acorda Therapeutics shares in Q2 2024, an estimated $114.
  • Fidelity Investments first reported a position in Acorda Therapeutics in Q2 2013 and held it in 31 quarters.
  • Fidelity Investments's Acorda Therapeutics position peaked at $277M in Q4 2015.
  • 2 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2024.

Based on Fidelity Investments's 13F filing for Q2 2024, filed 13 Aug 2024.